NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of BellRing Brands, Inc. (NYSE: BRBR) between November 19, 2024 and August 4, 2025, inclusive (the "Class Period†). BellRing develops, markets, and sells "convenient nutrition†products such as ready-to-drink ("RTD†) protein shakes primarily under the brand name Premier Protein. For more information, submit a form, email attorney Phillip Kim, or give us a ca ...

Group 1 - The core issue involves a class action lawsuit against Beyond Meat, Inc. for allegedly misleading investors about its business operations during the specified period [1][2] - The lawsuit claims that Beyond Meat's long-lived assets had a book value exceeding their fair value, indicating a likely need for a material, non-cash impairment charge [3] - It is alleged that these misstatements could impair Beyond Meat's ability to file periodic reports with the SEC in a timely manner, leading to investor damages when the truth was revealed [3] Group 2 - Shareholders interested in participating as lead plaintiffs must file motions by March 24, 2026, and can remain absent class members if they choose not to take action [4] - Rosen Law Firm operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless they recover losses [5] - Rosen Law Firm is recognized for its commitment to shareholder rights litigation and has successfully recovered over $1 billion for shareholders since its inception [6]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Stride, Inc. due to allegations of fiduciary duty breaches by the board of directors during a specified class period [2]. Group 1: Legal Investigation - A class action complaint was filed against Stride on November 11, 2025, concerning actions taken between October 22, 2024, and October 28, 2025 [2]. - The investigation focuses on whether Stride's board of directors has breached their fiduciary duties to the company [2]. Group 2: Allegations Against Stride - The complaint alleges that Stride made false and misleading statements about its success and capabilities in the education sector [8]. - Specific allegations include: 1. Inflating enrollment numbers by retaining "ghost students" [8]. 2. Cutting staffing costs by assigning teachers excessive caseloads beyond statutory limits [8]. 3. Ignoring compliance requirements, including background checks and licensure laws for employees, and federally mandated special education services [8]. 4. Suppressing whistleblowers who reported financial directives aimed at delaying hiring and denying services to maintain profit margins [8]. 5. Losing existing and potential enrollments due to these practices [8]. - These materially false statements led to the purchase of securities at artificially inflated prices, resulting in damages when the truth was revealed [8].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Fiserv, Inc. on behalf of long-term stockholders following a class action complaint filed against the company, focusing on possible breaches of fiduciary duties by the board of directors [1][6]. Group 1: Class Action Details - A class action complaint was filed against Fiserv on November 4, 2025, with a Class Period from July 23, 2025, to October 29, 2025 [1]. - The complaint alleges that during the Class Period, Fiserv made misleading statements regarding its initiatives and projects, particularly during a guidance revision in July 2025 [6]. - Fiserv's July 2025 guidance changes were based on a "re-underwriting" review, which the company later admitted was based on assumptions that were difficult to achieve [6]. Group 2: Impact on Investors - The misleading statements made by Fiserv during the Class Period resulted in investors purchasing the company's securities at artificially inflated prices, leading to damages when the truth was revealed [6]. - The company acknowledged in October 2025 that the guidance disclosed in July was fundamentally flawed, impacting investor trust and stock value [6].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit against Endeavour Group Holdings, Inc. for allegedly misleading investors regarding its business operations during the specified class period from January 15, 2025, to March 24, 2025 [1][2]. Allegations - The lawsuit claims that Endeavour Group Holdings made false and misleading statements in its January 15, 2025 Information Statement filed with the SEC, which misrepresented the true value of Endeavour's shares and failed to disclose executive earnings related to a take-private merger [3]. - Additionally, the complaint alleges that there were undisclosed conflicts of interest involving Endeavour's special committee and financial advisor [3]. Legal Proceedings - Former shareholders wishing to serve as lead plaintiffs must file motions with the court by March 18, 2026, and participation in the case is not required to be eligible for recovery [4]. - The representation in this lawsuit is on a contingency fee basis, meaning shareholders will not incur any fees or expenses [5]. About Rosen Law Firm - Rosen Law Firm is recognized for its active role in securities class actions and has successfully recovered over $1 billion for shareholders since its inception [6].

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Varonis Systems, Inc. (NASDAQ: VRNS) securities between February 5, 2025, and October 28, 2025, alleging that the company misled investors regarding its business prospects and revenue outlook [1][2]. Allegations - The complaint asserts that Varonis created a misleading impression of having reliable information about its projected revenue and growth, while downplaying risks associated with seasonality and macroeconomic factors [2]. - It is claimed that Varonis' optimistic reports on growth and cost-cutting measures did not align with reality, indicating that the company was not adequately prepared to sustain its annual recurring revenue growth without a high rate of quarterly conversions [2]. Financial Impact - On October 28, 2025, Varonis released third-quarter results that fell short of prior projections and subsequently lowered its full-year guidance. This led to a significant decline in the company's stock price, dropping from $63.00 per share to $32.34 per share, representing a decrease of approximately 48.67% in just one day [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must submit their papers to the court by March 9, 2026. Participation in the case is not required to be eligible for recovery [4].

Core Viewpoint - Robbins LLP is investigating allegations that Fermi Inc. misled investors regarding its business prospects, particularly related to its Project Matador campus [2]. Group 1: Allegations and Misleading Information - Fermi Inc. allegedly overstated tenant demand for its Project Matador campus [2]. - The company did not disclose the reliance on a single tenant's funding commitment for financing the construction of Project Matador [2]. - There was a significant risk that the tenant could terminate its funding commitment, which was not communicated to investors [2]. Group 2: Impact on Stock Price - On December 12, 2025, Fermi revealed that the first tenant for Project Matador had terminated its $150 million funding agreement, leading to a stock price drop of $5.16 per share, or 33.8%, closing at $10.09 [3]. - By the time of the class action announcement, Fermi's stock had traded as low as $8.59 per share, representing a 59% decline from the IPO price of $21.00 per share [3]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Fermi Inc., with a deadline to submit papers to the court by March 6, 2026, for those wishing to serve as lead plaintiff [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].

Core Viewpoint - A class action has been filed against Vistagen Therapeutics, Inc. for allegedly misleading investors regarding the viability of its Phase 3 trial study of fasedienol, leading to significant financial losses for shareholders [1][2]. Group 1: Allegations and Trial Results - Robbins LLP is investigating allegations that Vistagen Therapeutics misled investors about the success of its Phase 3 PALISADE-3 trial of fasedienol, which was intended for treating social anxiety disorder [2]. - On December 17, 2025, Vistagen announced that the PALISADE-3 trial did not show a statistically significant improvement on its primary endpoint, leading to a dramatic stock price decline from $4.36 to $0.86, a drop of over 80% [3]. Group 2: Class Action Participation - Shareholders who purchased Vistagen's common stock between April 1, 2024, and December 16, 2025, may be eligible to participate in the class action and can contact Robbins LLP to serve as lead plaintiff [1][4]. - Participation in the class action is not mandatory for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 3: Company Background - Vistagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neuropsychiatric and neurological disorders [1].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit against Bath & Body Works, Inc. for allegedly misleading investors regarding its business operations during the specified class period from June 4, 2024, to November 19, 2025 [1][2]. Allegations - The lawsuit claims that Bath & Body Works made materially false and misleading statements about its growth strategy, which included "adjacencies, collaborations, and promotions," failing to grow its customer base or achieve the projected net sales growth [3]. - It is alleged that as the company's strategy faltered, it relied on brand collaborations to mask weak financial results, leading to a failure to meet previously issued financial guidance [3]. - The lawsuit asserts that the positive statements made by the defendants regarding Bath & Body Works' business and prospects were materially misleading and lacked a reasonable basis, resulting in investor damages when the truth was revealed [3]. Next Steps - Shareholders interested in participating in the class action must file their motions to serve as lead plaintiff by March 16, 2026. A lead plaintiff represents the class in directing the litigation [4]. - Shareholders can choose to remain absent from the case while still being eligible for recovery [4]. About Rosen Law Firm - Rosen Law Firm is recognized for its commitment to shareholder rights litigation, having recovered over $1 billion for shareholders since its inception [6].

Core Viewpoint - A class action has been filed against Varonis Systems, Inc. for allegedly misleading investors about its business prospects and financial performance during the specified period [1][2]. Allegations - The complaint claims that Varonis misrepresented its revenue outlook and growth potential while downplaying risks associated with seasonality and macroeconomic factors [2]. - It is alleged that Varonis' optimistic reports regarding growth and cost-cutting measures did not reflect the reality of its sales effectiveness and ability to convert clients to its SaaS offerings [2]. Financial Impact - On October 28, 2025, Varonis reported third-quarter results that fell short of prior projections and subsequently lowered its full-year guidance [3]. - Following this announcement, Varonis' stock price plummeted from $63.00 per share to $32.34 per share, marking a decline of approximately 48.67% in just one day [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their papers by March 9, 2026, but participation is not required to be eligible for recovery [4]. - The representation in the class action is on a contingency fee basis, meaning shareholders will incur no fees or expenses [5].